In one paragraphArticle in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Stéphanie AndradeLEPABE, ALiCE, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.ORCID 0000-0001-6918-8775 Maria J RamalhoLEPABE, ALiCE, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.ORCID 0000-0003-2428-7520 João SantosLEPABE, ALiCE, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.
Sílvio SantosCEB-Centre of Biological Engineering, University of Minho, 4710-057 Braga, Portugal.
Luís D R MeloCEB-Centre of Biological Engineering, University of Minho, 4710-057 Braga, Portugal.
Nuno GuimarãesLEPABE, ALiCE, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.ORCID 0000-0002-7623-3877 Maria P FerrazDepartment of Mechanical Engineering, Faculty of Engineering, University of Porto, 4200-465 Porto, Portugal.ORCID 0000-0002-0274-106X Nuno F AzevedoLEPABE, ALiCE, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.ORCID 0000-0001-5864-3250 Maria C PereiraLEPABE, ALiCE, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.ORCID 0000-0001-8505-3432 Joana A LoureiroLEPABE, ALiCE, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal.ORCID 0000-0002-9841-3967 Funding
European Union's Horizon 2020 958174Fundação para a Ciência e Tecnologia CEEC-IND/01741/2021Fundação para a Ciência e Tecnologia https://doi.org/10.54499/2021.00221.CEEC-IND/CP1664/CT00022021.00221.CEECINDFundação para a Ciência e Tecnologia LA/P/0029/2020Fundação para a Ciência e Tecnologia LA/P/0045/2020Fundação para a Ciência e Tecnologia M-ERA-NET3/0001/2021Fundação para a Ciência e Tecnologia UIDB/00511/2020Fundação para a Ciência e Tecnologia UIDB/04469/2020Fundação para a Ciência e Tecnologia UIDP/00511/2020
6 · The paper itselfAbstract
Treating bacterial infections has become increasingly difficult due to the rise in antibiotic-resistant bacterial strains. Strategies involving the targeted delivery of antibiotics have been proposed to minimize the administered antibiotic doses. This study aims to develop the first double-modified nanovehicle capable of increasing bacterial membranes' permeability while specifically targeting
Indexed as
Anti-Bacterial AgentsFolic AcidNanoparticlesPolylactic Acid-Polyglycolic Acid CopolymerStaphylococcus aureusDrug CarriersDrug Delivery SystemsHumansMicrobial Sensitivity TestsAnti-Bacterial AgentsDrug CarriersFolic AcidPolylactic Acid-Polyglycolic Acid Copolymerantimicrobial resistancebacteria targetingbiocompatibilitycell-penetrating peptidedrug delivery system
Identifiers
PMID41226700
PMCPMC12608785
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390